Allogeneic stem cell transplantation remains the only curative therapy for myelofibrosis.
Despite advances in transplant, the morbidity and the mortality of the procedure necessitate …

Myelofibrosis is a rare hematologic malignancy with limited curative therapeutic options.
Significant advances in our understanding of disease pathogenesis have led to new targets …

Myelofibrosis with myeloid metaplasia (MMM) is a clonal disorder resulting from the
proliferation of aberrant hematopoietic progenitors. Hence MMM is curable if the abnormal …

Allogeneic haematopoietic stem-cell transplantation (HSCT) is the only curative treatment for
myelofibrosis. We retrospectively analyzed the outcome of patients who underwent …

Idiopathic myelofibrosis (IMF) is a clonal disorder resulting from the proliferation of aberrant
hematopoietic stem cells. Conventional treatment is unsatisfactory, and with the exception of …

Allogeneic haematopoietic stem‐cell transplantation (HSCT) is the only curative treatment
for myelofibrosis. We report an analysis of the Société Française de Greffe de Moelle et de …

Primary or post-ET/PV myelofibrosis is one of the Philadelphia-negative myeloproliferative
neoplasms with worst survival. Allogeneic stem cell transplantation (ASCT) can cure a …

Summary Allogeneic Haematopoietic Stem Cell Transplant (allo‐HSCT) remains the only
curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the …

Myelofibrosis, either de novo or following pre-existing hematologic diseases, can be cured
by allogeneic hematopoietic stem cell transplantation (SCT), but SCT is associated with …

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for
myelofibrosis. Most post-transplantation events occur during the first two years and hence …